InterCure Ltd. (INCR.TA)
| Previous Close | 785.80 |
| Open | 785.80 |
| Bid | 757.30 x 7471200 |
| Ask | 757.50 x 1676700 |
| Day's Range | 748.10 - 781.90 |
| 52 Week Range | 395.00 - 1,346.00 |
| Volume | |
| Avg. Volume | 185,641 |
| Market Cap | 349.375M |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference
NEW YORK & HERZLIYA, Israel, May 22, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City.
- Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
NEW YORK & HERZLIYA, Israel, May 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
- Business Wire
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
NEW YORK & HERZLIYA, Israel, April 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
